BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Teva Pharms Usa Inc	BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	212212	ANDA	Teva Pharmaceuticals, Inc.	0480-3080-31	1 POUCH in 1 CARTON (0480-3080-31) / 1 CANISTER in 1 POUCH / 120 AEROSOL, METERED in 1 CANISTER	2026-05-27
Teva Pharms Usa Inc	BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	212212	ANDA	Teva Pharmaceuticals, Inc.	0480-3081-31	1 POUCH in 1 CARTON (0480-3081-31) / 1 CANISTER in 1 POUCH / 120 AEROSOL, METERED in 1 CANISTER	2026-05-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: June 7, 2026

Budesonide and formoterol fumarate dihydrate are supplied through two supply chains: (1) active pharmaceutical ingredient (API) and critical intermediates and (2) finished-dose inhalation manufacturing, typically using metered-dose inhalers (MDIs) or dry powder inhalers (DPIs) depending on the specific branded or generic product.

Which companies supply Budesonide and Formoterol Fumarate Dihydrate APIs?

Featured snippet answer: The supply base for budesonide and formoterol fumarate dihydrate spans Indian, Chinese, and Western ingredient manufacturers, with inhalation-device finished-dose contracts concentrated in specialized inhalation CDMOs and large generic inhalation manufacturers.

Budesonide API suppliers and typical sourcing patterns

Budesonide is typically sourced from:

Category-leading steroid API manufacturers with established inhaled steroid production lines
Steroid intermediate specialists (for dihydroxy-functionalization and oxidation steps)
Multi-purpose hormonals plants that also produce inhaled or nasal corticosteroids

Formoterol fumarate dihydrate API suppliers and typical sourcing patterns

Formoterol fumarate dihydrate is typically sourced from:

Chiral-capable small-molecule API suppliers (process control around stereochemistry)
Specialty β-agonist API manufacturers
Fumarate salt suppliers that convert free base to the fumarate form under controlled crystallization conditions

What “suppliers” usually means in practice for inhaled combination products

For budesonide/formoterol combination products, buyers usually source:

Budesonide API (or budesonide micro-powder where relevant)
Formoterol fumarate dihydrate API
Excipients and formulation system components (carrier lactose for DPIs; ethanol/HFA system components for MDIs)
Inhaler/device manufacturing capacity under contract (CDMO)

What inhaler formulations use Budesonide and Formoterol Fumarate Dihydrate, and how does that change the supplier roster?

Featured snippet answer: Supplier selection changes materially by device type. Budesonide/formoterol combination is commonly commercialized as DPI (lactose carrier blend) and MDI (propellant-based formulation). Device and formulation suppliers differ by route.

DPI (dry powder inhaler) supply chain

DPI manufacturing usually involves:

Carrier lactose system sourcing and milling/blending control
Particle engineering and blend uniformity validation
Dry powder filling, dose metering, and device integration

Common buyer focus points:

Blend uniformity across lots
Tap density and flow characterization
Stability of budesonide under humidity/light exposure

MDI (metered-dose inhaler) supply chain

MDI manufacturing usually involves:

HFA propellant system sourcing and VOC-controlled handling
Surfactant/excipient selection for valve performance
Spray plume performance and droplet sizing validation

Common buyer focus points:

Valve coating compatibility and leachables
Spray pattern reproducibility
Container closure system performance

Which API manufacturers are the largest or most common for these inhalation actives?

Featured snippet answer: For budesonide and formoterol fumarate dihydrate, the largest procurement pools typically come from large-scale Asian API manufacturers plus specialized inhalation-focused intermediates providers, with Western and Japanese firms also present in some sourcing arrangements.

Typical procurement map used by branded manufacturers

Branded and large generics buyers often follow this pattern:

2 to 3 qualified API sources per active ingredient
One “primary” supplier for cost and capacity
One “backup” supplier for risk mitigation
Additional sources for regulatory/clinical comparability when bridging is needed

Typical procurement map for generics and CDMO-led development

Generics and CDMOs commonly:

Qualify API suppliers through abbreviated/ICH-based comparability packages
Standardize on established inhalation-compatible API grades
Use inhalation-experienced excipient sourcing partners

What suppliers provide Budesonide and Formoterol Fumarate Dihydrate as combination finished products?

Featured snippet answer: Finished-dose suppliers for budesonide/formoterol products include branded originators, established inhalation generics companies, and inhalation-focused CDMOs that handle formulation, filling, and device integration.

Brand-level supply versus contract manufacturing

Brand originators typically manufacture or contract manufacture finished doses with locked device specifications.
Generic entrants often contract inhalation CDMOs for formulation and device packaging.

Device integration is often the gating item

Even when the API is available, finished-dose release depends on:

Compatibility with actuator and valve components
Metering performance and emitted dose specifications
Aerosol plume geometry or powder dose dispersion targets

What critical intermediates and excipients affect supplier qualification for Budesonide and Formoterol?

Featured snippet answer: Supplier qualification hinges on chemical purity and solid-state properties for the APIs, and on inhalation performance characteristics for excipients.

Budesonide critical quality attributes (CQAs) tied to suppliers

Potency assay and impurity profile (including steroid-related degradants)
Particle size distribution where relevant to blend uniformity
Solvent residue limits, water content, and polymorph control where applicable

Formoterol fumarate dihydrate CQAs tied to suppliers

Salt form verification (fumarate dihydrate)
Impurities from amine chemistry and oxidative pathways
Moisture uptake and crystal habit consistency affecting dissolution and dosing

Excipients that constrain supplier choices

Lactose carrier grade and particle size distribution (DPI)
Controlled surfactants and valve lubricants (MDI)
Buffering/tonicity adjustments when stability models require it

How do buyers select suppliers for Budesonide/Formoterol under FDA and QbD expectations?

Featured snippet answer: Supplier selection tracks directly to chemistry manufacturing and controls (CMC) readiness: impurity control, batch reproducibility, and inhalation performance verification.

Supplier qualification checklist used by regulated buyers

DMF status for the API where used in filings (or technical package equivalence)
CoA traceability and impurity reporting detail
GMP compliance history and facility inspection record
Ability to produce inhalation-appropriate grades with consistent solid-state properties
Analytical methods transfer capability to the applicant’s lab or CDMO

Inhalation performance testing is a supplier interface

Even if API meets spec, end-product performance can fail if:

Powder blend flow is inconsistent across lots
Spray plume properties drift due to excipient grade shifts
Particle size distributions cause emitted dose variability

What patent and regulatory status affects who can supply Budesonide/Formoterol in the US?

Featured snippet answer: Regulatory entry barriers come from Orange Book-listed patents tied to specific formulations and device-delivery systems. Supplier access to the market depends on whether the entrant can launch without infringing formulation, method-of-use, or device-related patents.

How patent scope changes “who can supply”

If a branded product has formulation and device packaging patents, generic/contract supply must align with non-infringing manufacturing and CMC.
If method-of-use claims exist for COPD/asthma-related regimens, labeling and clinical comparability can constrain the entry strategy.

What this means operationally for supplier strategy

Development teams often preselect suppliers based on whether the resulting formulation can pass legal and CMC comparability.
Some supplier routes are used only for specific dosage forms to stay within patent and bioequivalence constraints.

Key Takeaways

Budesonide and formoterol fumarate dihydrate supply is split between API/critical-intermediate producers and inhalation formulation/device CDMOs.
DPI versus MDI changes the supplier roster, because excipient handling, blending, filling, and device integration differ.
Supplier qualification for regulated development is governed by impurity control, salt form/polymorph control, and inhalation performance specifications.
Market entry is constrained by product-specific regulatory and patent listings, so “suppliers” is partly determined by the intended dosage form and device delivery system.

FAQs

1) Who manufactures budesonide/formoterol fixed-dose inhalers under contract?

Contract manufacturing is typically handled by inhalation-specialist CDMOs and major inhalation-focused generics manufacturers with device integration capability.

2) Do budesonide and formoterol fumarate dihydrate come from the same suppliers?

Often not. Buyers commonly qualify separate suppliers for budesonide API and formoterol fumarate dihydrate API, then combine them at the formulation stage.

3) What is the most supplier-sensitive step in DPI manufacturing?

Lactose-carrier blending uniformity and dry powder filling controls are among the most critical supplier interfaces.

4) What is the most supplier-sensitive step in MDI manufacturing?

Valve compatibility, container closure system performance, and spray plume reproducibility are typically the gating factors.

5) What documentation matters most when qualifying API suppliers?

DMF/technical package completeness, detailed CoA impurity reporting, GMP compliance evidence, and batch reproducibility in inhalation-relevant grades matter most.

References

FDA. “Drug Master Files (DMF).” U.S. Food and Drug Administration.
FDA. “ANDA Submissions Requirements for Generic Drugs.” U.S. Food and Drug Administration.
FDA. “Current Good Manufacturing Practice (CGMP) Regulations.” U.S. Food and Drug Administration.
U.S. FDA. Orange Book (Drugs@FDA and Orange Book patent listings).

Suppliers and packagers for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE